The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen

British Journal of Clinical Pharmacology

Volumn 42, Issue 2, 1996, Pages 163-169

  Skeith, K J ^a   Dasgupta, M ^a   Lange, R ^b   Jamali, F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b BAYER AG   (Germany)

Author keywords

Acylglucuronide conjugates; Ketoprofen enantiomers; Pharmacokinetics; Renal impairment; Stereoselectivity

Indexed keywords

DRUG METABOLITE; KETOPROFEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; ENANTIOMER; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; STEREOSPECIFICITY;

EID: 0030036532     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03864.x     Document Type: Article

References (15)

1. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990; 19: 197-217.
2. Upton RA, Williams RL, Buskin MA, Jones RM. Effect of probenicid on ketoprofen kinetics. Clin Pharmacol Ther 1982; 31: 705-712.
3. Skeith KJ, Russell AS, Jamali F. Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function, and dose. J Clin Pharmacol 1993; 33: 1052-1059.
4. Stafanger G, Larsen HW, Hansen H, Sorensen K. Pharmacokinetics of ketoprofen in patients with chronic renal failure. Scand J Rheumatol 1981; 10: 189-192.
5. Halstenson CE, Ermer JC, Cevallos WH, Boyce E, Conrad KA, Chiang ST. The effect of renal disease on ketoprofen disposition. J Clin Pharmacol 1992; 32: 751 (abstract).
6. Sallustio BC, Purdie YJ, Whitehead AG, Ahern MJ, Meffin PJ. The disposition of ketoprofen enantiomers in man. Br J Clin Pharmacol 1988; 26, 765-770.
7. Hayball PJ, Nation RL, Bochner F, Sansom LN, Ahern MJ, Smith MD. The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 36: 185-193.
8. Advenier C, Roux A, Gobert C, Massias P, Varoquaux O, Flouvat B. Pharmacokinetics of ketoprofen in the elderly. Br J Clin Pharmacol 1983; 16: 65-70.
9. Dennis MJ, French PC, Crome P, Babiker M, Shillingford J, Hopkins R. Pharmacokinetic profile of controlled release ketoprofen in elderly subjects. Br J Clin Pharmacol 1985; 20: 567-573.
10. Foster RT, Jamali F, Russell AS, Alballa SR. Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses. J Pharm Sci 1988; 77: 191-195.
11. Palylyk E, Jamali F. Simultaneous determination ketoprofen enantiomers and probenecid in plasma and urine by high-performance liquid chromatography. J Chromatogr 1991; 568: 187-196.
12. Jamali F, Alballa RS, Mehvar R, Lemko CH. Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. Ther Drug Monit 1988; 10: 91-96.
13. Foster RT, Jamali F, Russell AS. Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid. Eur J Clin Pharmacol 1989; 37: 589-594.
14. Hayball PJ, Nation RL, Bochner F, et al. Plasma protein binding of ketoprofen enantiomers in man: Method development and its application. Chirality 1991; 3: 460-466.
15. Jamali F, Russell AS, Foster RT, Lemko CH. Ketoprofen pharmacokinetics in humans: Evidence of enantiomeric inversion and lack of interaction. J Pharm Sci 1990; 79: 460-461.